FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 03/2022”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the European Life Sciences sector.

As of the top of  March 2022 we establish the next present VC developments in Europe:

  • In 2022, total Life Sciences funding has reached EUR 2,880m so farTop 5 Offers exceed EUR 70m every, largest transaction amounted to EUR 500m in Doctolib (France)
  • Bpifrance dominates the Prime 5 Buyers (by deal quantity), adopted by Eurazeo (France) and Normal Atlantic (United States)
  • The Biotech sector acquired 42% of the entire funding quantity, no change in comparison with the earlier month
  • Oncology dominates as the highest indication of the Biotechnology sector

To entry the complete report, please click on right here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink

Leave a Reply

Your email address will not be published.